Clazosentan in Aneurysmal Subarachnoid Hemorrhage "CONSCIOUS-3"

Terminated

Phase 3 Results N/A

Summary of Purpose

The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH treated by... Trial Stopped: Lack of efficacy data from the Phase 3 clinical study (AC-054-301; CONSCIOUS-2)

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 28 April 2015.

1 Jul 2009 13 Jul 2009 1 Oct 2010 1 Jan 2011 1 Apr 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available